


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of formula (IA) or a pharmaceutically acceptable salt thereof:



formula (IA)

wherein:

$Y^1$  and  $Y^2$  are both O;

z is  $NR^8$ , O or S;

n is 0 or 1;

W is  $NR^1$ ,  $CR^1R^2$  or a bond;

V is  $NR^{15}SO_2$ ;

t is 0 or 1;

B is a group selected from aryl, heteroaryl and heterocyclyl where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano,  $C_{1-4}$ alkyl (optionally substituted by  $R^9$  or  $C_{1-4}$ alkoxy or one or more halo),  $C_{2-4}$ alkenyl (optionally substituted by halo or  $R^9$ ),  $C_{2-4}$ alkynyl (optionally substituted by halo or  $R^9$ ),  $C_{3-6}$ cycloalkyl (optionally substituted by  $R^9$  or one or more halo),  $C_5$ .

cycloalkenyl (optionally substituted by halo or  $R^9$ ), aryl (optionally substituted by halo or  $C_{1-4}$ alkyl), heteroaryl (optionally substituted by halo or  $C_{1-4}$ alkyl), heterocyclyl (optionally substituted by  $C_{1-4}$ alkyl),  $-SR^{11}$ ,  $-SOR^{11}$ ,  $-SO_2R^{11}$ ,  $-SO_2NR^9R^{10}$ ,  $-NR^9SO_2R^{11}$ ,  $-NHCONR^9R^{10}$ ,  $-OR^9$ ,  $-NR^9R^{10}$ ,  $-CONR^9R^{10}$  and  $-NR^9COR^{10}$ ; or B is  $C_{2-4}$ alkenyl or  $C_{2-4}$ alkynyl, each being optionally substituted by a group selected from  $C_{1-4}$ alkyl,  $C_{3-6}$ cycloalkyl, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more halo, nitro, cyano, trifluoromethyl, trifluoromethoxy,  $-CONHR^9$ ,  $-CONR^9R^{10}$ ,  $-SO_2R^{11}$ ,  $-SO_2NR^9R^{10}$ ,  $-NR^9SO_2R^{11}$ ,  $C_{1-4}$ alkyl or  $C_{1-4}$ alkoxy;

$R^1$  and  $R^2$  are independently hydrogen or a group selected from  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{3-6}$ cycloalkyl and  $C_{5-6}$ cycloalkenyl which the group may be optionally substituted by halo, cyano, nitro, hydroxy or  $C_{1-4}$ alkoxy;

$R^3$ ,  $R^4$ ,  $R^5$  and  $R^6$  are independently hydrogen or a group selected from  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl,  $C_{3-6}$ cycloalkyl,  $C_{5-6}$ cycloalkenyl, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy,  $C_{1-4}$ alkyl,  $C_{2-4}$ alkenyl,  $C_{2-4}$ alkynyl,  $C_{3-6}$ cycloalkyl (optionally substituted by one or more  $R^{17}$ ), aryl (optionally substituted by one or more  $R^{17}$ ), heteroaryl (optionally substituted by one or more  $R^{17}$ ), heterocyclyl,  $-OR^{18}$ ,  $-SR^{19}$ ,  $-SOR^{19}$ ,  $-SO_2R^{19}$ ,  $-COR^{19}$ ,  $-CO_2R^{18}$ ,  $-CONR^{18}R^{20}$ ,  $-NR^{16}COR^{18}$ ,  $-SO_2NR^{18}R^{20}$  and  $-NR^{16}SO_2R^{19}$ ; or  $R^1$  and  $R^3$  together with the nitrogen or carbon atoms and carbon atom to which they are respectively attached form a saturated 3- to 7-membered ring optionally containing 1 or 2 heteroatoms groups selected from NH, O, S, SO and  $SO_2$  where the ring is optionally substituted on carbon by  $C_{1-4}$ alkyl,  $C_{1-3}$ alkoxy or fluoro and/or on nitrogen by  $-COC_{1-3}$ alkyl,  $-SO_2C_{1-3}$ alkyl or  $C_{1-4}$ alkyl;

or  $R^3$  and  $R^4$  together with the carbon atom to which they are attached form a saturated 3- to 7-membered ring optionally containing a heteroatom group selected from NH, O, S, SO and  $SO_2$  where the ring is optionally substituted on carbon by  $C_{1-4}$ alkyl,  $C_{1-3}$ alkoxy or fluoro and/or on nitrogen by  $-COC_{1-3}$ alkyl,  $-SO_2C_{1-3}$ alkyl and/or  $C_{1-4}$ alkyl;

or  $R^3$  and  $R^5$  together with the carbon atoms to which they are attached form a saturated 3- to 7-membered ring optionally containing a heteroatom group selected from NH, O, S, SO and  $SO_2$  where the ring is optionally substituted on carbon by  $C_{1-4}$ alkyl,  $C_{1-3}$ alkoxy or fluoro and/or on nitrogen by  $-COC_{1-3}$ alkyl,  $-SO_2C_{1-3}$ alkyl or  $C_{1-4}$ alkyl;

or  $R^5$  and  $R^6$  together with the carbon atom to which they are attached form a saturated 3- to 7-membered ring optionally containing a heteroatom group selected from NH, O, S, SO and  $SO_2$  where the ring is optionally substituted on carbon by  $C_{1-4}$ alkyl,  $C_{1-3}$ alkoxy or fluoro and/or on nitrogen by  $-COC_{1-3}$ alkyl,  $-SO_2C_{1-3}$ alkyl or  $C_{1-4}$ alkyl;

$R^7$  is hydrogen or a group selected from  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl, heteroalkyl,  $C_{3-7}$ cycloalkyl, aryl, heteroaryl and heterocyclyl where the group is optionally substituted by halo,  $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy,  $C_{3-7}$ cycloalkyl, heterocyclyl, aryl, heteroaryl or heteroalkyl; and wherein the group from which  $R^7$  may be selected is optionally substituted on the group and/or on its optional substituent by one or more substituents independently selected from halo, cyano,  $C_{1-4}$ alkyl, nitro, halo $C_{1-4}$ alkyl, heteroalkyl, aryl, heteroaryl, hydroxy $C_{1-4}$ alkyl,  $C_{3-7}$ cycloalkyl, heterocyclyl,  $C_{1-4}$ alkoxy $C_{1-4}$ alkyl, halo $C_{1-4}$ alkoxy $C_{1-4}$ alkyl,  $-COC_{1-4}$ alkyl,  $-OR^{21}$ ,  $-NR^{21}R^{22}$ ,  $-CO_2R^{21}$ ,  $-SR^{25}$ ,  $-SOR^{25}$ ,  $-SO_2R^{25}$ ,  $-NR^{21}COR^{22}$ ,  $-NR^{21}CO_2R^{22}$ ,  $-CONR^{21}R^{22}$  and  $-NHCONR^{21}R^{22}$ ;

or  $R^3$  and  $R^7$  together with the carbon atoms to which they are each attached and  $(CR^5R^6)_n$  form a saturated 5- to 7-membered ring optionally containing a heteroatom group selected from NH, O, S, SO and  $SO_2$  where the ring is optionally substituted on carbon by  $C_{1-4}$ alkyl,  $C_{1-3}$ alkoxy or fluoro and/or on nitrogen by  $-COC_{1-3}$ alkyl,  $-SO_2C_{1-3}$ alkyl or  $C_{1-4}$ alkyl;

$R^8$  is selected from hydrogen or methyl;

$R^9$  and  $R^{10}$  are independently hydrogen,  $C_{1-6}$ alkyl or  $C_{3-6}$ cycloalkyl;

or  $R^9$  and  $R^{10}$  together with the nitrogen to which they are attached form a heterocyclic 4- to 7-membered ring;

$R^{11}$  is  $C_{1-6}$ alkyl or  $C_{3-6}$ cycloalkyl;

$R^{12}$  and  $R^{13}$  are independently selected from hydrogen,  $C_{1-6}$ alkyl and  $C_{3-6}$ cycloalkyl;

$R^{15}$  is hydrogen or  $C_{1-3}$ alkyl;

**R**<sup>16</sup> is hydrogen or C<sub>1-6</sub>alkyl;

**R**<sup>17</sup> is selected from halo, C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl and C<sub>1-6</sub>alkoxy;

**R**<sup>18</sup> is hydrogen or a group selected from C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>5-6</sub>cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, arylC<sub>1-4</sub>alkyl and heteroarylC<sub>1-4</sub>alkyl where the group is optionally substituted by one or more halo;


**R**<sup>19</sup> and **R**<sup>25</sup> are independently a group selected from C<sub>1-6</sub>alkyl, C<sub>3-6</sub>cycloalkyl, C<sub>5-6</sub>cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, arylC<sub>1-4</sub>alkyl and heteroarylC<sub>1-4</sub>alkyl where the group is optionally substituted by one or more halo;

**R**<sup>20</sup> is hydrogen, C<sub>1-6</sub>alkyl or C<sub>3-6</sub>cycloalkyl;

or **R**<sup>18</sup> and **R**<sup>20</sup> together with the nitrogen atom to which they are attached form a heterocyclic 4- to 7- membered ring;

**R**<sup>21</sup> and **R**<sup>22</sup> are independently hydrogen, C<sub>1-4</sub>alkyl, haloC<sub>1-4</sub>alkyl, aryl and arylC<sub>1-4</sub>alkyl; provided a compound of formula (IA) is not 1-(4-methyl-2,5-dioxoimidazolidin-4-yl)-N-[4-(4-chlorophenoxy)phenyl]methanesulphonamide.

2. (Currently amended) A compound of formula (IB) or a pharmaceutically acceptable salt thereof:



formula (IB)

wherein:

**Y**<sup>1</sup> and **Y**<sup>2</sup> are independently O;

**z** is NR<sup>8</sup>, O or S;

**n** is 0 or 1;

**W** is NR<sup>1</sup>;

V is SO<sub>2</sub> or CO;

t is 0 or 1;

B is a group selected from aryl, heteroaryl and heterocyclyl where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano, C<sub>1-4</sub>alkyl (optionally substituted by R<sup>9</sup> or C<sub>1-4</sub>alkoxy or one or more halo), C<sub>2-4</sub>alkenyl (optionally substituted by halo or R<sup>9</sup>), C<sub>2-4</sub>alkynyl (optionally substituted by halo or R<sup>9</sup>), C<sub>3-6</sub>cycloalkyl (optionally substituted by R<sup>9</sup> or one or more halo), C<sub>5-6</sub>cycloalkenyl (optionally substituted by halo or R<sup>9</sup>), aryl (optionally substituted by halo or C<sub>1-4</sub>alkyl), heteroaryl (optionally substituted by halo or C<sub>1-4</sub>alkyl), heterocyclyl (optionally substituted by C<sub>1-4</sub>alkyl), -SR<sup>11</sup>, -SOR<sup>11</sup>, -SO<sub>2</sub>R<sup>11</sup>, -SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>, -NR<sup>9</sup>SO<sub>2</sub>R<sup>11</sup>, -NHCONR<sup>9</sup>R<sup>10</sup>, -OR<sup>9</sup>, -NR<sup>9</sup>R<sup>10</sup>, -CONR<sup>9</sup>R<sup>10</sup> and -NR<sup>9</sup>COR<sup>10</sup>; or B is C<sub>2-4</sub>alkenyl or C<sub>2-4</sub>alkynyl, each being optionally substituted by a group selected from C<sub>1-4</sub>alkyl, C<sub>3-6</sub>cycloalkyl, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, -CONHR<sup>9</sup>, -CONR<sup>9</sup>R<sup>10</sup>, -SO<sub>2</sub>R<sup>11</sup>, -SO<sub>2</sub>NR<sup>9</sup>R<sup>10</sup>, -NR<sup>9</sup>SO<sub>2</sub>R<sup>11</sup>, C<sub>1-4</sub>alkyl or C<sub>1-4</sub>alkoxy;

provided that when t is 0 such that B is directly attached to the oxygen atom shown in formula (IB) and B is monocyclic aryl, monocyclic heteroaryl or monocyclic heterocyclyl and n is 0 then the monocyclic group that is B is substituted on one of the atoms adjacent to the atom to which the oxygen is attached, by a group selected from those listed above in the definition of B which optionally substitute B;

R<sup>1</sup> and R<sup>3</sup> together with the nitrogen and carbon atoms to which they are respectively attached form a saturated 3- to 7-membered ring optionally containing a further heteroatom group selected from NH, O, S, SO and SO<sub>2</sub> where the ring is optionally substituted on carbon by C<sub>1-4</sub>alkyl, fluoro or C<sub>1-4</sub>alkoxy and/or on nitrogen by -COC<sub>1-3</sub>alkyl, -SO<sub>2</sub>C<sub>1-3</sub>alkyl or C<sub>1-4</sub>alkyl; R<sup>4</sup>, R<sup>5</sup> and R<sup>6</sup> are independently hydrogen or a group selected from C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>3-6</sub>cycloalkyl, C<sub>5-6</sub>cycloalkenyl, aryl, heteroaryl and heterocyclyl which group is optionally substituted by one or more substituents independently selected from halo, nitro, cyano, trifluoromethyl, trifluoromethoxy, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, C<sub>3-6</sub>cycloalkyl

(optionally substituted by one or more  $R^{17}$ ), aryl (optionally substituted by one or more  $R^{17}$ ), heteroaryl (optionally substituted by one or more  $R^{17}$ ), heterocyclyl,  $-OR^{18}$ ,  $-SR^{19}$ ,  $-SOR^{19}$ ,  $-SO_2R^{19}$ ,  $-COR^{19}$ ,  $-CO_2R^{18}$ ,  $-CONR^{18}R^{20}$ ,  $-NR^{16}COR^{18}$ ,  $-SO_2NR^{18}R^{20}$  and  $-NR^{16}SO_2R^{19}$ ; or  $R^5$  and  $R^6$  together with the carbon atom to which they are attached form a saturated 3- to 7-membered ring optionally containing a heteroatom group selected from NH, O, S, SO and  $SO_2$  where the ring is optionally substituted on carbon by  $C_{1-4}$ alkyl, fluoro or  $C_{1-4}$ alkoxy and/or on nitrogen by  $-COC_{1-3}$ alkyl,  $-SO_2C_{1-3}$ alkyl or  $C_{1-4}$ alkyl;

$R^7$  is hydrogen or a group selected from  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl, heteroalkyl,  $C_{3-7}$ cycloalkyl, aryl, heteroaryl or heterocyclyl where the group is optionally substituted by halo,  $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy,  $C_{3-7}$ cycloalkyl, heterocyclyl, aryl, heteroaryl and heteroalkyl; and wherein the group from which  $R^7$  may be selected is optionally substituted on the group and/or on its optional substituent by one or more substituents independently selected from halo, cyano,  $C_{1-4}$ alkyl, nitro, halo $C_{1-4}$ alkyl, heteroalkyl, aryl, heteroaryl, hydroxy $C_{1-4}$ alkyl,  $C_{3-7}$ cycloalkyl, heterocyclyl,  $C_{1-4}$ alkoxy $C_{1-4}$ alkyl, halo $C_{1-4}$ alkoxy $C_{1-4}$ alkyl,  $-COC_{1-4}$ alkyl,  $-OR^{21}$ ,  $-NR^{21}R^{22}$ ,  $-CO_2R^{21}$ ,  $-SR^{25}$ ,  $-SOR^{25}$ ,  $-SO_2R^{25}$ ,  $-NR^{21}COR^{22}$ ,  $-NR^{21}CO_2R^{22}$ ,  $-CONR^{21}R^{22}$  and  $-NHCONR^{21}R^{22}$ ;

$R^8$  is selected from hydrogen or methyl;

$R^9$  and  $R^{10}$  are independently hydrogen,  $C_{1-6}$ alkyl or  $C_{3-6}$ cycloalkyl;

or  $R^9$  and  $R^{10}$  together with the nitrogen to which they are attached form a heterocyclic 4- to 7-membered ring;

$R^{11}$  is  $C_{1-6}$ alkyl or  $C_{3-6}$ cycloalkyl;

$R^{12}$  and  $R^{13}$  are independently selected from hydrogen,  $C_{1-6}$ alkyl and  $C_{3-6}$ cycloalkyl;

$R^{16}$  is hydrogen or  $C_{1-6}$ alkyl;

$R^{17}$  is selected from halo,  $C_{1-6}$ alkyl,  $C_{3-6}$ cycloalkyl and  $C_{1-6}$ alkoxy;

$R^{18}$  is hydrogen or a group selected from  $C_{1-6}$ alkyl,  $C_{3-6}$ cycloalkyl,  $C_{5-6}$ cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, aryl $C_{1-4}$ alkyl and heteroaryl $C_{1-4}$ alkyl where the group is optionally substituted by one or more halo;

$R^{19}$  and  $R^{25}$  are independently a group selected from  $C_{1-6}$ alkyl,  $C_{3-6}$ cycloalkyl,

C<sub>5-6</sub>cycloalkenyl, saturated heterocyclyl, aryl, heteroaryl, arylC<sub>1-4</sub>alkyl and heteroarylC<sub>1-4</sub>alkyl where the group is optionally substituted by one or more halo;

R<sup>20</sup> is hydrogen, C<sub>1-6</sub>alkyl or C<sub>3-6</sub>cycloalkyl;

or R<sup>18</sup> and R<sup>20</sup> together with the nitrogen to which they are attached form a heterocyclic 4- to 7-membered ring;

R<sup>21</sup> and R<sup>22</sup> are independently hydrogen, C<sub>1-4</sub>alkyl, haloC<sub>1-4</sub>alkyl, aryl and arylC<sub>1-4</sub>alkyl.

3. (Currently amended) A compound according to claim 1 ~~or 2~~ wherein t is 1.

4. (Currently amended) A compound according to claim 1 wherein B is phenyl, naphthyl, pyridyl, imidazolyl, quinoliny, cinnolyl, isoquinoliny, thienopyridyl, naphthyridinyl, 2,5-methylenedioxyphenyl, 3,4-methylenedioxyphenyl, thienopyrimidinyl, pyrimidinyl, thienyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazinyl, pyridoimidazolyl, benzimidazolyl, benzofuranyl, benzothienyl, indolyl, benzothiazolyl, benzotriazolyl, benzisoxazolyl, benzisothiazolyl, indazolyl, indoliziny, isobenzofuranyl, quinazolinyl, imidazopyridinyl, pyrazolopyridinyl, indoliny, tetrahydroquinoliny, tetrahydroisoquinoliny and isoindoliny, where each is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano, C<sub>1-4</sub>alkyl (optionally substituted by one or more fluoro), C<sub>2-4</sub>alkynyl, heteroaryl, -OR<sup>9</sup>, -NR<sup>9</sup>R<sup>10</sup>, -CONR<sup>9</sup>R<sup>10</sup> and -NR<sup>9</sup>COR<sup>10</sup>; or B is vinyl or ethynyl optionally substituted by C<sub>1-4</sub>alkyl; and R<sup>9</sup> and R<sup>10</sup> are as defined in claim 1.

5. (Currently amended) A compound according to claim 1 wherein B is bicyclic aryl, bicyclic heteroaryl or bicyclic heterocyclyl optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano, C<sub>1-4</sub>alkyl (optionally substituted by R<sup>9</sup> or C<sub>1-4</sub>alkoxy, or one or more halo), C<sub>2-4</sub>alkenyl (optionally substituted by halo or R<sup>9</sup>), C<sub>2-4</sub>alkynyl (optionally substituted by halo or R<sup>9</sup>), C<sub>3-6</sub>cycloalkyl (optionally substituted by R<sup>9</sup> or one or more halo), C<sub>5-6</sub>cycloalkenyl (optionally substituted by

halo or  $R^9$ ), aryl (optionally substituted by halo or  $C_{1-4}$ alkyl), heteroaryl (optionally substituted by halo or  $C_{1-4}$ alkyl), heterocyclyl (optionally substituted by  $C_{1-4}$ alkyl),  $-SR^{11}$ ,  $-SOR^{11}$ ,  $-SO_2R^{11}$ ,  $-SO_2NR^9R^{10}$ ,  $-NR^9SO_2R^{11}$ ,  $-NHCONR^9R^{10}$ ,  $-OR^9$ ,  $-NR^9R^{10}$ ,  $-CONR^9R^{10}$  and  $-NR^9COR^{10}$ ; and  $R^9$ ,  $R^{10}$  and  $R^{11}$  are as defined in claim 1.

6. (Currently amended) A compound according to claim 1 ~~or 3~~ wherein B is 2-methylquinolin-4-yl or 2,5-dimethylphenyl.

7. (Currently amended) A compound according to claim 2 wherein t is 1 and B is phenyl, naphthyl, pyridyl, imidazolyl, quinoliny, cinnolyl, isoquinoliny, thienopyridyl, naphthyridinyl, 2,5-methylenedioxyphenyl, 3,4-methylenedioxyphenyl, thienopyrimidinyl, pyrimidinyl, thienyl, pyrrolyl, pyrazolyl, thiazolyl, oxazolyl, isoxazolyl, pyrazinyl, pyridoimidazolyl, benzimidazolyl, benzofuranyl, benzothienyl, indolyl, benzothiazolyl, benzotriazolyl, benzisoxazolyl, benzisothiazolyl, indazolyl, indoliziny, isobenzofuranyl, quinazolinyl, imidazopyridinyl, pyrazolopyridinyl, indolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl and isoindolinyl, where each is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano,  $C_{1-4}$ alkyl (optionally substituted by one or more fluoro),  $C_{2-4}$ alkynyl, heteroaryl,  $-OR^9$ ,  $-NR^9R^{10}$ ,  $-CONR^9R^{10}$  and  $-NR^9COR^{10}$ ; or B is vinyl or ethynyl optionally substituted by  $C_{1-4}$ alkyl; and  $R^9$  and  $R^{10}$  are as defined in claim 2.

8. (Currently amended) A compound according to claim 2 wherein B is a group selected from bicyclic aryl, bicyclic heteroaryl and bicyclic heterocyclyl, where each group is optionally substituted by one or more groups independently selected from nitro, trifluoromethyl, trifluoromethoxy, halo, cyano,  $C_{1-4}$ alkyl (optionally substituted by  $R^9$  or one or more halo),  $C_{2-4}$ alkenyl (optionally substituted by halo or  $R^9$ ),  $C_{2-4}$ alkynyl (optionally substituted by halo or  $R^9$ ),  $C_{3-6}$ cycloalkyl (optionally substituted by  $R^9$  or one or more halo),  $C_{5-6}$ cycloalkenyl (optionally substituted by halo or  $R^9$ ), aryl (optionally substituted by halo or  $C_{1-4}$ alkyl), heteroaryl (optionally substituted by halo or  $C_{1-4}$ alkyl), heterocyclyl (optionally substituted by  $C_{1-4}$ alkyl),  $-$



$SR^{11}$ ,  $-SOR^{11}$ ,  $-SO_2R^{11}$ ,  $-SO_2NR^9R^{10}$ ,  $-NR^9SO_2R^{11}$ ,  $-NHCONR^9R^{10}$ ,  $-OR^9$ ,  $-NR^9R^{10}$ ,  $-CONR^9R^{10}$  and  $-NR^9COR^{10}$ ; or B is  $C_{2-4}$ alkenyl or  $C_{2-4}$ alkynyl, each being optionally substituted by a group selected from  $C_{1-4}$ alkyl,  $C_{3-6}$ cycloalkyl, aryl, heteroaryl, heterocyclyl which group is optionally substituted by one or more halo, nitro, cyano, trifluoromethyl, trifluoromethoxy,  $-CONHR^9$ ,  $-CONR^9R^{10}$ ,  $-SO_2R^{11}$ ,  $-SO_2NR^9R^{10}$ ,  $-NR^9SO_2R^{11}$ ,  $C_{1-4}$ alkyl or  $C_{1-4}$ alkox; and  $R^9$ ,  $R^{10}$  and  $R^{11}$  are as defined in claim 2.

9. (Original) A compound according to claim 2 wherein B is 2-methylquinolin-4-yl.

10. (Currently amended) A compound according to ~~any one of the preceding claims~~ claim 1 wherein  $R^7$  is hydrogen or a group selected from  $C_{1-4}$ alkyl, aryl $C_{1-4}$ alkyl, heteroaryl $C_{1-4}$ alkyl, heterocyclyl $C_{1-4}$ alkyl, aryl, heteroaryl, heterocyclyl and  $C_{3-5}$ cycloalkyl which group is optionally substituted by cyano,  $C_{1-4}$ alkyl, halo,  $-OR^{21}$ ,  $-CO_2R^{21}$  and  $-NR^{21}CO_2R^{22}$ .

11. (Currently amended) A compound according to ~~any one of claims 1 to 9~~ claim 1 wherein  $R^7$  is hydrogen or a group selected from  $C_{1-4}$ alkyl, tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, morpholinyl optionally substituted by one or more  $C_{1-4}$ alkoxy, fluoro,  $-COC_{1-3}$ alkyl or  $-SO_2C_{1-3}$ alkyl.

12. (Currently amended) A compound according to ~~any one of claims 1 to 9~~ claim 1 wherein  $R^7$  is  $C_{1-4}$ alkyl optionally substituted by halo, hydroxy,  $C_{1-4}$ alkoxy or amino.


13-14. (Cancelled)

15. (Currently amended) A method of treating inflammatory diseases, autoimmune disease, allergic/atopic diseases, transplant rejection, graft versus host disease, cardiovascular disease, reperfusion injury and malignancy ~~in a warm blooded animal, such as man, in need of such~~

~~treatment~~ which comprises administering ~~to said animal an effective amount of~~ a compound according to ~~any one of claims 1 to 12~~ claim 1.

16. (Currently amended) A pharmaceutical composition comprising a compound according to claim 1 ~~or claim 2~~ and a pharmaceutically-acceptable diluent or carrier.


17. (Currently amended) A process for preparing a compound according to claim 1 ~~or claim 2~~, ~~comprises comprising~~ the steps of converting a ketone or aldehyde of formula (IIA) or (IIB) into a compound of formula (IA) or (IB);



and thereafter if necessary:


- converting a compound of the formula (IA) or (IB) into another compound of the formula (IA) or (IB);
- removing any protecting groups;
- forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.

18. (Original) A process for preparing a compound according to claim 1 which when W is NR<sup>1</sup> comprises:



reaction of an amine of formula (VIIIA) with a suitable chlorosulphonamide intermediate under standard sulphonamide formation conditions; or

when W is a bond or CR<sup>1</sup>R<sup>2</sup>, comprises



reaction of a hydantoin sulphonyl chloride of formula (XVA) with a suitable chlorosulphonamide intermediate under standard sulphonamide formation conditions; and thereafter if necessary:

- converting a compound of the formula (IA) into another compound of the formula (IA);
- removing any protecting groups;
- forming a pharmaceutically acceptable salt or *in vivo* hydrolysable ester.